Atossa Therapeutics, Inc. (ATOS) Stock Analysis

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer

Tue, July 28, 2026 at 12:30 PM UTC 2 min read

Atossa Therapeutics announced the publication of research highlighting novel (Z)-endoxifen-related compounds that exhibit strong anti-cancer activity in ER-positive breast cancer. This development is significant for investors as it underscores the company's ongoing innovation in cancer treatment, potentially enhancing its product pipeline and market position. Positive advancements in clinical research could lead to increased investor confidence and potential future revenue growth for Atossa.

Read full article →

Atos achieves CMMC 2.0 Level 2 certification, strengthening readiness for mission-critical and complex defense programs

Thu, July 23, 2026 at 4:59 PM UTC 4 min read

Atos has successfully attained CMMC 2.0 Level 2 certification, enhancing its capabilities for mission-critical and complex defense programs. This certification is significant for investors as it positions Atos to better compete for government contracts, potentially leading to increased revenue and growth opportunities in the defense sector. The achievement underscores the company's commitment to security and compliance, which are crucial in attracting clients in the defense industry.

Read full article →